Actuarial Studies: Financial Impact of H.R. 3, “Lower Drug Costs Now Act of 2019”
Guidance for this memorandum summarizes the Office of the Actuary’s (OACT’s) estimates of Titles I and II of H.R. 3, “Lower Drug Costs Now Act of 2019,” which was introduced on September 19, 2019. Included are estimates of the proposal’s effects on Medicare, Medicaid, the Federal Health Insurance Marketplace, and elements of the national health expenditures.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: November 20, 2019
This memorandum summarizes the Office of the Actuary’s (OACT’s) estimates of Titles I and II of H.R. 3, “Lower Drug Costs Now Act of 2019,” which was introduced on September 19, 2019. Included are estimates of the proposal’s effects on Medicare, Medicaid, the Federal Health Insurance Marketplace, and elements of the national health expenditures. We will update this analysis to include the effects of Title III of the legislation as time permits.
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.